Fuentes Tania, Kearns-Jonker Mary
Department of Pathology and Human Anatomy, Loma Linda University School of Medicine, Loma Linda, CA, USA.
Stem Cells Cloning. 2013 Mar 25;6:1-12. doi: 10.2147/SCCAA.S29221.
Stem cell-based therapies hold promise for regenerating the myocardium after injury. Recent data obtained from phase I clinical trials using endogenous cardiovascular progenitors isolated directly from the heart suggest that cell-based treatment for heart patients using stem cells that reside in the heart provides significant functional benefit and an improvement in patient outcome. Methods to achieve improved engraftment and regeneration may extend this therapeutic benefit. Endogenous cardiovascular progenitors have been tested extensively in small animals to identify cells that improve cardiac function after myocardial infarction. However, the relative lack of large animal models impedes translation into clinical practice. This review will exclusively focus on the latest research pertaining to humans and large animals, including both endogenous and induced sources of cardiovascular progenitors.
基于干细胞的疗法有望在损伤后使心肌再生。最近从使用直接从心脏分离出的内源性心血管祖细胞进行的I期临床试验中获得的数据表明，使用存在于心脏中的干细胞对心脏病患者进行细胞治疗可带来显著的功能益处，并改善患者的预后。实现更好的植入和再生的方法可能会扩大这种治疗益处。内源性心血管祖细胞已在小动物中进行了广泛测试，以确定在心肌梗死后能改善心脏功能的细胞。然而，相对缺乏大型动物模型阻碍了其转化为临床应用。本综述将专门关注与人类和大型动物相关的最新研究，包括心血管祖细胞的内源性和诱导性来源。
